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CHAPTER 1. INTRODUCTION
In recent decades, cancer imaging has advanced beyond the determination
of size and location of lesions to defining the biological properties of tumors. One
of the most powerful tools to dynamically measure tumor activity is positron
emission tomography (PET), a form of nuclear medicine imaging which utilizes
small doses of radioactive tracers to produce three dimensional images. While
PET can provide morphological information about solid tumors, the novelty of PET
imaging over other modalities is its ability to non-invasively provide information
about the metabolic behavior of tumors.

This allows both physicians and

researchers to gain insight into the tumors which may aid in determining the best
options for treatment, as well as monitor tumor response to therapies. In this way,
PET is one of the diagnostic modalities at the forefront of personalized medicine
for cancer patients.
1. Basic PET Physics and Tracer Synthesis
PET is performed by injection of a radioactive tracer, and scans are
acquired on by detection of emitted photons. Tracers for PET are designed to
incorporate positron emitting nuclides, such as 18F or 64Cu. Upon decay, positrons
are released from the nuclide and subsequently collide with an electron in the
surrounding area.

This collision, or annihilation, releases two photons with

energies of 511 keV in opposite directions (1). PET utilizes rings of crystal blocks
to quantitate emitted photons (2, 3).by detecting coincidence pairs of photons in
all directions around the object being scanned. Subsequently, a statistical map of
describing the probable 3-dimensional location of tracer is generated.

After
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allowing for distance traveled by the positron prior to annihilation, tissue scatter,
and coincidental detection of non-paired photons (“random” events), clinical PET
scanners typically have a spatial resolution of about 4-5 mm (4). Preclinical PET
scanners for small animal imaging typically have better resolution, due to the
smaller diameter of the crystal rings (5, 6). This leads to resolution of about 1-2
mm in PET images acquired during small animal imaging (7-9). Additionally, the
detection of only 511 keV photons by the PET crystals results in excellent
sensitivity, often between 10-11 and 10-12 mol/L of tracer required to obtain an
image (10). Tracers synthesized for PET often exhibit high specific activity which,
combined with PET detection sensitivity, allows for image acquisition with a
relatively small mass of tracer required (2).
Tracers for PET are be rationally designed to image biological processes of
interest to acquire valuable biochemical information (11). Depending on their
atomic properties, positron emitting nuclides can be incorporated into biologically
active molecules. For example,

18F

is can be substituted for a hydroxyl group,

such as at the C-2 position of glucose to form 2-deoxy-2-18F-fluorodeoxyglucose,
or 18F-FDG (12) .

18F-FDG

is thought to be retained in metabolically active tissues

following uptake mediated by glucose transporter 1, or GLUT1 followed by
phosphorylation by hexokinase (13).

18F-FDG

was one of the first FDA-approved

tracers for PET for a variety of applications. It is relatively easy to synthesize, and
18F

is widely available. In utilizing a glucose analogue,

18F-FDG

images can

identify tissues that are metabolically active, such as brain and heart (14).
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Additionally, proliferating tumors utilize circulating glucose during cellular
metabolism.
Another commonly used tracer in PET is
18F-FLT

18F-fluorothymidine,

or

18F-FLT.

is a thymidine analogue that is taken up by cells through the salvage

pathway of DNA synthesis (15). Mimicking endogenous thymidine,

18F-FLT

is

trapped in rapidly dividing cells which are rapidly dividing, such as tumor. Thus,
18F-FLT

serves as a marker of cellular proliferation with PET (16).

1.1. Biological Implications of PET Interpretation
Although the mechanism of tracer quantitation during PET is always
coincidence detection of 511 keV photons, PET tracers can be designed to image
a multitude of tissue properties. As with

18F-FDG

and

18F-FLT,

positron emitting

nuclides can be incorporated into a variety of small biologically active molecules
to image their activity in tissues of interest. Further, nuclides can be incorporated
into larger structures, such as nanoparticles, to determine their delivery to tissues
such as solid tumors (17, 18). Importantly, the amount of tracer required for PET
imaging is normally too small to disrupt the kinetics of endogenous molecules,
ensuring that the tracer will not alter biochemical pathways and confound scans
(19).
PET can measure specific processes of tumors for the purpose of
classification, predicting treatment success, and monitoring tumor response to
therapy over time. Tracers for PET are often able to detect or probe for subtle
changes in tumor metabolism or intratumoral biochemistry. PET scans offer the
opportunity to measure metabolic changes which occur in response to therapy (20-
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22). For example,

18F-FDG

has been studied in the clinic as a prognostic marker

for progression free survival and overall survival prior to treatment with antivascular
agents in patients with metastatic renal cell carcinoma (23).

18F-FDG

was similarly

able to predict overall survival and metastasis-free survival in early hepatocellular
carcinoma prior to surgery (24). In studies with

18F-FLT,

researchers have been

able to assess early responses to sunitinib treatment in patients with metastatic
renal cell carcinoma (25).

18F-FLT

imaging has also been shown to identify

progression of pancreatic cancer early into gemcitabine treatment, to potentially
select patients that may benefit from alternative therapeutic options (26).
Importantly, different tumors can exhibit varying levels of tracer uptake. Baseline
uptake should be considered when choosing tracers to monitor therapeutic
response in cancers, as one tracer is not likely to be suitable for all cases.
While identifying tumor location, size, and stage are important aspects of
imaging in oncology, PET can provide specific information about the biological
characteristics of an individual tumor. By designing tracers to measure biological
pathways of interest, PET can be used to quantitate these tumor characteristics in
ways which impact therapeutic decisions. Measuring early changes in tumor
metabolism and behavior which result from treatment can provide individualized
information about a patient’s likelihood of response (11, 27, 28). The ability to
identify responders early into treatment would allow physicians to make the best
therapeutic decisions for cancer patients. Imaging with PET is an invaluable tool
for the personalization of medicine for solid tumors.
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2. PET for Early Detection of Therapeutic Effects on Solid Tumors
In clinical oncology, one of the most promising aspects of PET research is
the potential to image early tumor response to therapy. Although new therapies
for a multitude of cancers are being developed each year, measurable response
to cancer treatments are extremely heterogenous in patient populations (29-31).
Traditionally, patients and their physicians were forced to wait until months of
treatment are completed to determine the extent, if any, of therapeutic efficacy.
Thus, a means by which physicians could predict therapeutic success or failure
early into cancer treatments could save patients valuable time, resources, and
avoid unnecessary side effects.
The principle of measuring early metabolic consequences of successful
therapy has been demonstrated using
been performed to evaluate

18F-FDG

18F-FDG

imaging. Multiple studies have

PET in measuring early response to breast

cancer treatment, including one of the first of such studies in patients published by
Wahl et al. (32). Patients were scanned with

18F-FDG

before beginning the first

cycle of chemotherapy, and at multiple time points throughout therapy.
Interestingly, significant reductions in 18F-FDG uptake were observed in as little as
8 days, and continued through day 60 of treatment in women who responded to
therapy. Conversely, little change was observed in PET of women who were later
identified as non-responders. In another example, by Buvat et al., aimed to identify
PET measurement thresholds of early therapeutic response in metastatic
colorectal cancer patients receiving chemotherapy (33). The authors found that
after 14 days of therapy, standardized uptake values (SUV) of tumors with

18F-

6

FDG PET were able to predict response when compared to pre-treatment scans.
In thymic epithelial tumors, Segreto et al. measured

18F-FDG

uptake in tumors

before and after three cycles of chemotherapy (34). Similarly, the authors found
that changes in

18F-FDG

uptake following partial therapy differed between

responders and non-responders. In each of these studies, the authors noted that
early changes in

18F-FDG

morphology. In this way,

uptake preceded any measurable changes in tumor

18F-FDG

PET has demonstrated the utility of measuring

metabolic changes to assess early therapeutic effects in cancer and results with a
number of tumor types and treatments have been explored (35-37).
Although

18F-FDG

is among the most commonly used tracers utilized for

PET, multiple forms of radiolabeled small molecules and macromolecules are
currently being studied as tracers to image early response to therapy. With the
increasing interest in precision personalized medicine, tracers are being
developed as companions to therapy in order to offer insight into unique behavior
of a patient’s disease. One strategy revolves around developing tracers which
mimic a targeted therapeutic agent in order to assess availability of the target or
successful delivery of the treatment (38, 39). Another approach is the design of
tracers to measure downstream or biologically-related processes in order to
measure the effect of a treatment (40, 41). In each case, although the effects of
the therapeutic strategies may face heterogeneous response in patient
populations, companion imaging offers a means by which clinicians and
researchers can more efficiently plan and assess successful treatments for
patients on an individual basis.
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3. Imaging of Nanoparticle Distribution to Assess Treatments that Alter
Delivery
As interest in nanoparticles (NP) for delivery of therapeutic agents to solid
tumors grows, methods to measure or predict their utility are critically needed.
Imaging NP can streamline the development and implementation of NP
treatments, and can serve as tools for personalized medicine. NP platforms for
drug delivery are used to enhance drug deposition in tumor tissues to increase
effective therapeutic doses (42). However, preclinical successes in treating tumors
with NP are often met with failure in human trials due to ineffective delivery to
tumors in the heterogeneous patient population (43, 44).
By providing non-invasive, quantitative measures of NP localization,
imaging can provide invaluable information of NP distribution in tumors. With
imaging, the delivery of NP can be assessed in a patient or lesion, predict
therapeutic efficacy of NP treatments, and monitor distribution over time or as a
response to treatment.

While ineffectual NP delivery in human tumors has

hampered the path to the clinic, researchers are now considering the use of
therapies which alter the tumor and its microenvironment to improve NP delivery
(45). The use of imaging to quantify NP delivery could identify and characterize
novel methods for improving NP localization to solid tumors. In the clinic, these
same NP-based imaging tools can be used to personalize treatments by predicting
therapeutic outcomes, identifying barriers to delivery, and monitoring changes in
delivery throughout the course of treatment.
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“Nanotheranostics” to visualize delivery with non-invasive imaging
In addition to delivering therapeutic payloads, many NP can be designed or
modified for imaging to act as a tracer or contrast agent. Imaging with NP
(diagnostic NP; Dx-NP) that mimic the systemic distribution of drug-loaded NP
(therapeutic NP; Tx-NP) can assess the tumor-targeting capacity of the NP
platform.
Recently, coupling of targeted therapies with complimentary diagnostic
imaging has been termed “theranostics” (46). From this, the emerging field of
“nanotheranostics” provides tools to measure NP delivery which may predict
efficacy of NP therapy on an individual basis (47, 48). Examples of a variety of NP
for imaging are outlined in Table 1.

While imaging with Dx-NP to predict

therapeutic response has been the goal of nanotheranostics, the potential utilities
of imaging in NP research are myriad.

Dx-NP can measure the release of

payloads, or assess drug availability (49). Non-invasive scans can be repeated
over time to monitor delivery through the course of treatment. Perhaps the newest
and least explored utility for nanotheranostics is in evaluating strategies to improve
NP deposition in tumors with therapies that have an impact on enhanced
permeability and retention (EPR). Imaging with Dx-NP can allow researchers and
clinicians evaluate how therapies such as radiation, chemotherapy, and antivascular agents affect the delivery of NP.

Utilizing imaging with NP could

streamline NP development, identify the best combination therapies and treatment
timelines, and narrow the gap between preclinical studies and clinical application
of NP.
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Table 1. Examples of nanoparticle platforms for imaging

Platform

Name

Tumor Model

Modality

Therapeutic
Component

Ref.

Liposomal GdDTPA

Colon

DCE-MRI

None

(50)

MM-302

HER2+ breast

PET

Dox; AntiHER2 antibody
fragment

(51)

Fluorescentlylabeled
liposomes

Murine colon

NiR Imaging

None

(52)

Fluorescent
PEGylated
siRNAlipoplexes
Liposomal
iodine

Murine colon

NiR Imaging

siBcl-2

(53)

Primary
sarcoma

CT

None

(54)

99Tc-liposomes

Feline soft
tissue
sarcoma

Gamma
camera

None

(55)

99mTc-DSPE-

Rat
fibrosarcoma

Gamma
camera

None

(56)

Head and
neck;
Squamous cell
carcinoma

SPECT

Dox

(57,
58)

HPMA-Dox

Prostate

MRI

Dox

(59)

HPMAgemcitabine

Prostate

Gamma
camera

Gemcitabine

(59)

Liposome

PEG2000

99Tc-labeled

liposomal Dox

Copolymers

10
Dendrimer
G8-Gd-D

Squamous cell
carcinoma

MRI

None

(60)

Ferumoxyol
(Feraheme)

Murine
mammary;
Pancreas
Breast

MRI

None

(61,
62)

NiR Imaging

None

(63)

Albumin(GdDTPA)30

Breast

DCE-MRI

None

(64)

Gadofosveset
trisodium
(albumin bound)

Mouse
mammary

MRI

None

(61)

Iron oxide
nanoparticles

Angiospark680
Macromolecular
Complexes
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Enhanced Permeability and Retention
NP have long been thought to localize to solid tumors via EPR. Tumors
generate aberrant blood vessels which can harbor gap openings of between 400
and 600 nm (65). Coupled with poor lymphatic drainage, leaky tumor vasculature
causes large particles to become trapped in tumor interstitial spaces (66). NP,
which are usually 10 to 100 nm, have been shown preclinically to passively
accumulate in tumors due to EPR, often regardless of targeting surface moieties
(67, 68).
Perhaps the most commonly cited barrier to therapeutic NP efficacy is
delivery to and penetration of tumor tissues, despite preclinical results (43, 69).
Researchers have since suggested that EPR is hampered in humans by conditions
of high interstitial fluid pressures (IFP), increased pericyte coverage, inconsistent
vessel pore sizes, and thicker collagen and extracellular matrix (ECM) layers (7073). The parameters which define EPR are highly variable in patients, and are
based on dynamic conditions that change over time.
The task of improving NP accumulation in solid tumors can be viewed from
two perspectives: (1) adjustment of the physical parameters of the NP, and (2)
therapeutic modulation of the tumor and its microenvironment (74). Studies of the
former are already actively utilizing imaging (75, 76).

By adding diagnostic

components to the NP platform, researchers can measure differences in systemic
distribution of NP during the design, modification, or fine-tuning of NP. This can
mean manipulating size and shape, surface chemistry, targeting moieties, etc.
(77).
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The latter describes the use of therapeutic interventions which make tumor
tissues more available to NP infiltration. Many currently-accessible treatments
have the capacity to influence EPR parameters (78). To improve NP delivery,
multiple groups are utilizing therapies that affect tumor blood flow, vascular
permeability, IFP, and ECM components (79, 80). The goal is to reduce or remodel
the physical barriers to macromolecular profusion in human tumors, and provide
therapeutic avenues to improve outcomes of NP which are already in or near
clinical trials.

Nanotheranostics studies utilize various imaging modalities to

measure and monitor differences in NP distribution patterns which result from
additional therapies/interventions. A summary of these studies is provided in Table
2. These studies identify tools and techniques for personalization of NP therapies
for cancer.

13 therapeutically-altered NP delivery
Table 2. Preclinical studies of Imaging NPs for measuring
Therapeutic
Strategy

Treatment

Drug

VEGFR
inhibition

Axitinib

Alk5
inhibition

NP Imaging
Probe

Modality

Observed Effect

Ref

Albumin(GdDTPA)30

DCE-MRI

Reduced vascular
permeability of NP

(64)

LY-364947

Ferumoxytol
(Feraheme)

MRI

Modest improvement of
enhancement
throughout tumor

(61)

A-83-01

Liposomal GdDTPA

DCE-MRI

Increased AUC of Gd
accumulation in tumor

(50)

Cyclophosphamide

64

Cu-MM-302
(HER2-targeted
liposomal Dox)

PET

Reduced IFP;
increased liposomal
delivery to tumors;
improved Tx efficacy

(51)

S-1 (Tegafur)

Fluorescent
PEGylated
liposomes

NiR
Imaging

Increased liposomal
delivery; increased
homogeneity

(52)

Fluorescent
siRNA lipoplexes

NiR
Imaging

Increased uptake of
lipoplexes in tumors;
improved therapeutic
efficacy

(53)

G8-Gd-D

MRI

Increased
enhancement at
multiple time points

(60)

Liposomal Iodine

Dualenergy CT

Increased iodine
concentrations in
tumors; increased
permeability

(54)

HPMA-Dox (Gd)

MRI

Enhanced tumor
localization; increased
efficacy and toxicity

(59)

HPMAgemcitabine (131I)

Gamma
Camera

Enhanced tumor
localization; increased
efficacy, modest
toxicity

(59)

Angiospark680

NiR
Imaging

Increased
accumulation of probe
in tumors; increased
efficacy of subsequent
Doxil Tx

(63)

Targeting
Tumor
Vasculature

Tumor
Debulking
Cytotoxic
Therapy

Radiation
Single
High-Dose
RT

N/A
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Thermal
Ablation
Microwave
Ablation

N/A

99

Gamma
Camera

Increased liposome
accumulation in tumor

(55)

Warm
Water
Catheter

N/A

99m

Tc-DSPEPEG2000

Gamma
Camera

(56)

Radiofrequency
thermal
ablation

N/A

99

Tc-Liposomal
Dox

Gamma
Camera;
SPECT

Increased liposome
accumulation in tumor;
increased Dox delivery
with subsequent Doxil
Tx
Increased liposome
delivery to tumor;
increased levels of Dox
in resected tumor
tissues

Collagen
remodeling

Collagenase-2

99

SPECT

Transient drop in IFP;
increased intratumoral
Doxil localization

(58)

Losartin

Ferumoxytol

MRI

Increased tumor blood
pool as measured with
ferumoxytol; enhanced
uptake of subsequent
SMI drugs

(62)

Targeting
ECM and
BM

Tc-Liposomes

Tc-Doxil

(57)
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Changes in NP Delivery Due after Therapeutically Targeting Tumor Vasculature
Large pores and gaps in tumor vessel walls allow for extravasation of
macromolecules in circulation, including NP (81).

These characteristics are

heterogeneous in clinical populations, making them a somewhat difficult target for
cancer therapies (82).

Although often lacking widespread impact as

monotherapies, drugs which target angiogenesis or vessel integrity have been
shown to improve outcomes when combined with chemotherapy (83, 84). One
example is bevacizumab (AvastinTM; Genentech, San Francisco, CA), a vascular
endothelial growth factor (VEGF)-targeted antibody which is FDA approved in
combination with chemotherapy in multiple tumor types (85). Another example is
ziv-aflibercept injection (Zaltrap®, Sanofi and Regeneron Pharmaceuticals, Inc.,
Tarrytown, NY), which is a recombinant fusion protein which contains domains
which bind to portions of VEGF, and has been FDA approved for combination with
chemotherapy in colon cancer (86).

However, the ability to modulate tumor

vasculature properties is an attractive concept when facing the problem of
inconsistent NP distribution in tumors. Thus, agents which target a number of
vascular properties have been suggested as a means of altering EPR to enhance
NP delivery.
3.1. Imaging the Effects of Targeting Tumor Angiogenesis on NP Deposition
in Solid Tumors
Anti-angiogenic therapies like bevacizumab are designed to disrupt tumor
blood vessel formation and ultimately starve tumors of nutrients. These drugs
have led to modest improvements in clinical outcomes when combined with
conventional chemotherapy (83, 84).

16

3.1.1. Anti-VEGF therapies
While depletion of blood vessels is the intended outcome of anti-angiogenic
therapy, there is some evidence that these drugs cause temporary remodeling or
“normalization” of blood vessels, which may affect drug delivery for a short time
(87, 88). With the expanding use of anti-angiogenic therapies in the clinic, a
complete understanding of their effect on NP delivery will be important as N5P
enter clinical trials, and treatment regimens.
A study performed by Wilmes et al. measured the effect of blocking VEGF
signaling on perfusion of small and large contrast agents with DCE-MRI in BT474
breast tumor xenografts in mice (64). The group utilized a novel small molecule
inhibitor of VEGF receptor tyrosine kinase, axitinib (AG-013736; Inlyta; Pfizer,
NY, NY) to disrupt tumor vessel properties and growth. Administration of the drug
for three weeks showed dramatic antitumor action. DCE-MRI images to measure
early drug effects were obtained with both macromolecular albumin-bound
gadolinium-bound

diethylenetriaminepentaacetic

acid

(GdDTPA)

and

low

molecular weight GdDTPA contrast agents before and after axitinib therapy.
After only seven days of axitinib administration, the authors noted a marked
decrease in tumor perfusion compared to control tumors.

Reduced vessel

permeability was evident from significant drops in tumor endothelial transfer
coefficients (Kps) calculated for both contrast agents. Histology staining for CD31
performed in resected tumor tissues showed a reduced number of microvessels
after seven days of treatment, which complements the imaging data.

The

measurable decrease in albumin-bound GdDTPA perfusion into tumor tissues
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following short-term axitinib therapy suggests that imaging with DCE-MRI can
provide early and dynamic measures of changes in macromolecular distribution.
This study indicates that macromolecular delivery to tumors can be dramatically
altered by therapeutic intervention, and provides rationale for utilizing imaging to
measure these effects early into treatment.
3.1.2. Targeting TGF-β
Multiple studies have demonstrated that NP accumulation in solid tumors
can be enhanced by treatment with agents which cause tumor vessels to become
leaky (89, 90). A popular target is the transforming growth factor (TGF)-β pathway,
since blocking the kinase activity of the TGF-β1 receptor has been shown to
increase tumor vessel leakage (91). Drugs that inhibit TGF-βR1, also known as
activin-like kinase 5 (Alk5), are widely available and relatively well characterized,
which simplifies their incorporation into nanotheranostic studies.
Daldrup-Link et al. chose to utilize MR imaging to measure the effect of
Alk5-inhibitor

[3-(pyridine-2-yl)-4-(4-quinonyl)]-1H-pyrazole

(LY-364947

Calbiochem, San Diego, CA) on the delivery of NP-based contrast agents in
transgenic mouse mammary tumor virus-driven expression of the polyoma middle
T oncogene (MMTV-PyMT) adenocarcinoma, as well as an orthotopic
glioblastoma model (61).

MRI images were performed with gadofosveset

trisodium (Ablavar), a small molecule contrast agent which binds albumin to form
macromolecular complexes in circulation, as well as ferumoxytol (Feraheme), an
iron oxide NP.

Images were obtained at baseline, and following 6 days of
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treatment with LY-364947, i.p. every other day to visualize the effect of Alk5
inhibition on NP delivery.
In tumors subjected to Alk5 inhibition, tumor enhancement increased
threefold compared to controls in MR images with gadofosveset, primarily in the
tumor periphery, and twofold in images with ferumoxytol, throughout tumor tissues.
The authors suggest that Alk5 inhibition may be able to improve NP delivery and
efficacy, and that this effect can be visualized with NP contrast agents for MR
imaging. In this way, image-guided modulation of TGF-β signaling can be used to
personalize NP therapies.
Another study, carried out by Minowa et al. in mice bearing colon 26 tumors,
measured the effect of Alk5 inhibition with A-83-01 on NP delivery by performing
DCE-MRI with liposomal Gd-DTPA. The authors compared baseline scans to
scans acquired 24 hours after initiating treatment, which consisted of two injections
of A-83-01. Compared to baseline scans, treatment resulted in a 3.8-fold increase
in the AUC of Gd concentration (Figure 1). This implies that even short-term Alk5
inhibition can markedly improve liposome delivery to the tumor. Importantly,
imaging with a liposomal contrast agent for MRI was able to identify improved
liposomal delivery very early into Alk5 inhibition with A-83-01.

4. PET with Radiolabeled Pyrimidine Analogs for Early Assessment of Drug
Efficacy in Tumors
Just as oncologists have relied on tissue biopsies to help define and stage
tumors, PET images can be used to quantitatively assess the metabolic behavior
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of tumors. However, while biopsies involve invasive procedures and produce a
limited sample, PET images non-invasively provide information about the entire
tumor and surrounding tissues. In this way, PET is ideal for longitudinal studies of
tumor metabolism and for measuring changes in response to therapy (92, 93).
While response to treatment is usually confirmed by morphological changes in
tumor tissues (e.g. tumor size, tissue necrosis, etc.) (94), PET can measure
biochemical shifts indicative of therapeutic response prior to any noticeable
changes in tumor morphology.
PET Imaging of Cellular Proliferation
Although many studies have demonstrated the usefulness of 18F-FDG PET
in evaluating cancer treatment response, FDG imaging has limitations (95). As a
radiolabeled form of glucose, 18F-FDG is capable of measuring changes in glucose
metabolism that result from treatment. Tumor cells often exhibit a highly glycolytic
metabolism, whereby glucose is converted to lactate for ATP synthesis. This
occurs in lieu of ATP generation through oxidative phosphorylation (96). Increased
glucose consumption is one of the primary reasons that 18F-FDG is expected to be
taken up in greater amounts by tumor tissues (97). However, there is evidence
that 18F-FDG uptake is not ubiquitous in all tumors, and can be affected by a variety
of different tumor- or microenvironment-specific mechanisms (98-100). In fact,
18F-FDG

uptake in tumors, while still an important tool for clinicians, may not

provide the most direct measure of tumor response to therapy. Thus, other tracers
developed for PET may provide a more straightforward measure of early
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therapeutic response in tumors by measuring processes which are directly related
to tumor survival and progression.

Pyrimidine Analogues
One of the fundamental traits of a tumor is the ability to maintain and
increase proliferative behavior (101). Cells in proliferative tissues must duplicate
their DNA to divide, a process requiring availability of purines and pyrimidines.
Cellular consumption of thymidine is favored for measuring DNA synthesis and cell
division. Compared to other nucleosides, thymidine is only incorporated in nuclear
DNA, and not utilized in forming RNA (102).

Exogenous uptake of natural

thymidine in cells correlates with S phase of the cell cycle. To exploit the direct
relationship between cellular thymidine salvage and cellular division for tumor
imaging, multiple radiolabeled thymidine analogues have been developed for PET
(103).
Of the thymidine analogues for oncological PET, 3'-[18F]fluoro-3'deoxythymidine (18F-FLT) is the most widely accepted and utilized (104, 105). The
replacement of the 3’ hydroxyl group on a thymidine molecule with

18F

allows the

tracer to be taken up into cells and phosphorylated, but not incorporated into
growing DNA without inducing termination (106).

18F-FLT

is phosphorylated by

thymidine kinase 1 (TK1), which traps it within cells following incorporation (15).
18F-FLT

has been suggested as a marker of proliferation in tumors by measuring

TK1 activity during its metabolism via the thymidine salvage pathway (107). Tracer
uptake correlates with immunohistochemical staining for proliferation marker Ki-67
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in subsequently resected tissues (108). Clinically,

18F-FLT

PET is used to

approximate tumor proliferation, offering insight into the aggressiveness of a tumor
and its capacity to progress.
Although less commonly studied than

18F-FLT,

other thymidine analogues

have been developed as PET tracers. These include, but are not limited to FMAU
(1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)thymine), FIAU (2'-fluoro-2'-deoxy1-beta-D-arabinofuranosyl-5-iodo-uracil), and FAU (1-(2′-deoxy-2′-fluoro-β-darabinofuranosyl) uracil) (103).

Of these,

18F-FMAU

has been of interest for

imaging proliferation in tumors as an alternative to 18F-FLT. The fluorine group on
18F-FMAU

is attached at the 2’ position of thymidine, leaving the 3’ hydroxyl group

intact for 18F-FMAU incorporation into DNA (109). An advantage of 18F-FMAU over
18F-FLT

for PET is that

18F-FMAU

does not demonstrate the same high uptake in

tissues like bone marrow, making identification of tumors in these tissues more
feasible (110). One limitation of both FLT and FMAU is high uptake in the liver of
humans, which is due to metabolism rather than proliferation (111, 112)(refs). This
is likely due to the nature of FMAU phosphorylation which, unlike FLT, occurs
predominantly by thymidine kinase 2 (TK2), not TK1 (102). Interestingly, TK2
phosphorylation of thymidine (and its analogues) is associated with the synthesis
of mitochondrial DNA, not nuclear DNA (113). While both 18F-FLT and 18F-FMAU
are taken up by tumor tissues during thymidine salvage, the phosphorylation of
these by TK1 and TK2 respectively leads to differential retention. This, in turn,
requires distinct interpretation of PET scans performed with either tracer.
FLT and predicting therapeutic response
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While studies of the other thymidine analogues remain relatively limited,
multiple researchers have suggested that the utility of 18F-FLT lies in imaging early
response to therapy. Tumor tissues, while normally rapidly dividing, often slow or
stall proliferative processes when under stress caused by treatment (102). The
effects of anticancer drugs, particularly of drugs which target DNA synthesis, have
been measured early into treatment with

18F-FLT

(107).

In preclinical studies of 18F-FLT PET in lymphoma, Graf et al. found that 18FFLT uptake significantly decreased in tumors treated with doxorubicin after only 48
hours (114). Similarly, Ullrich et al. found that 18F-FLT uptake in erlotinib-sensitive
non-small cell lung tumors significantly decreased after two days of therapy
compared to drug-resistant controls (115).

A clinical study in esophageal

squamous cell cancer patients, performed by Chen et al., demonstrated that

18F-

FLT scans performed before and 4 weeks into chemotherapy or radiotherapy could
distinguish between responders and non-responders (116). It is important to note
that in these studies 18F-FLT was directly compared to 18F-FDG, and in each case
18F-FDG

did not have the predictive power demonstrated by 18F-FLT. The growing

base of evidence supporting the use of

18F-FLT

in predicting response early into

cancer treatment has strengthened the utility of PET in oncology (117). Further,
the variety of other thymidine analogue tracers could lead to new methods for
measuring the early effect of therapies for a variety of cancers.
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CHAPTER 2. LIPOSOMAL 64CU-PET IMAGING OF ANTI-VEGF DRUG
EFFECTS ON LIPOSOMAL DELIVERY TO COLON CANCER XENOGRAFTS.
1. Introduction
Globally, colorectal cancer (CRC) is the third most common cancer in men
(approximately 746,000 cases) and the second most common in women
(approximately 614,000 cases) as of 2012 (118, 119). The push for precision
medicine has led to a greater understanding of the molecular and genetic subtypes
of CRC among the population (120-123), and promoted the search for prognostic
and predictive biomarkers.

However, while multiple molecular markers have

shown promise as prognostic indicators (124, 125), attempts to utilize them in the
clinic have led to conflicting results (126-129). Thus, tumor stage and supporting
histological analysis remain the primary basis for therapeutic decision making in
CRC (130, 131).
In addition to the search for prognostic markers for CRCs, research has also
focused on uncovering better drug options. Standard cytotoxic agents for CRC
include 5-fluorouricil (5FU), often combined with irinotecan and/or oxaliplatin (131139). In patients with advanced disease almost all patients still develop resistance
to treatment and succumb to tumor growth (140, 141). Targeted antibodies are
regularly used in treating mCRC, including agents which target vascular
endothelial growth factor (VEGF) and its receptor (VEGFR) (142). Targeting of
VEGF pathways in CRC is designed to reduce tumor blood supply by disrupting
tumor vessels, and has had some success in the clinic (143, 144). One such
therapy is bevacizumab (bev; Avastin™; Genentech, San Francisco, CA), a VEGFtargeted monoclonal antibody, has been approved for CRC patients in combination
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with various chemotherapy regimens. Unfortunately, most therapeutic options in
CRC have faced the problem of resistance in the clinic, often due to the
heterogeneous nature of colon tumors (144-148).
Recently, there has been a growing interest in the development of
nanoparticle-based therapies, such as liposomes (LP), for cancer as multiple
preclinical studies have shown notable success in cellular and animal models (149155). Clinical trials utilizing LP for CRC treatment focus primarily on delivery of

well-characterized drugs, including irinotecan and its metabolite, SN-38, or
doxorubicin (130, 156, 157). LP deposition in solid tumors is heavily influenced by
enhanced permeability and retention (EPR), making the state of tumor blood
vessels a key factor in delivery. Theranostic approaches for imaging delivery of
LP could provide vital insight into the probability of success when treating with LP
platforms for drug delivery (158-160). In this study, we have utilized a 64Cu-loadable
liposome formulation to image the effects of short-term bev treatment on LP
delivery to colon tumor xenografts in mice. We chose to target tumor vasculature,
as the state of vessels in solid tumors is critical in defining EPR, and thus
macromolecular delivery (161-163). Although the long-term effects of bev on tumor
vasculature have been established, there is evidence that bev begins altering
tumor vessels and affecting vascular permeability early into treatment (164). Thus,
we aimed to measure any early changes in LP localization induced by short-term
bev with PET, and monitor subsequent therapy with liposomal irinotecan (LP-I;
MM-398; Onivyde®; Merrimack Pharmaceuticals Inc., Cambridge MA). In doing
so, we generated a system to measure dynamic changes in LP deposition which
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could affect the efficacy of LP-based therapies on an individual basis.
Furthermore, we were able to non-invasively measure significant differences in LP
delivery between bev-treated tumors and control tumors early into bev treatment.
Finally, the results seen with PET correlated with subsequent monitoring of
treatment efficacies, suggesting that this platform could have utility in predicting
and monitoring therapeutic LP success.
2. Materials and Methods
Materials
HT-29 cells and McCoy’s 5a Modified Medium were purchased from ATCC
(Manassas, VA) and kept below 15 passages following receipt. 4-DEAP-ATSC
chelator, empty MM-DX-929 liposomes, and LP-I were provided by Merrimack
Pharmaceuticals, Inc. (Cambridge, MA).

64CuCl
2

was purchased from the

Department of Radiology at Washington University (St. Louis, MO). Chelation
efficiency was measured with iTLC-SG plates (Agilent Technologies, Santa Clara,
CA). Loading efficiency was assessed with Sephadex G-50 DNA Grade Illustra
Nick columns (GE Healthcare, Pittsburg, PA).
Gamma spectroscopy was performed on a Packard Cobra II gamma
counter (Perkin-Elmer Inc., Waltham, MA). PET scans were acquired on an R4
microPET (Concorde Microsystems, Knoxville, TN). CT images were acquired
using an Inveon microSPECT/CT (Siemens Preclinical Imaging Solutions,
Malvern, PA). Images were registered and analyzed using PMOD Image Matching
and Fusion Tool ver3.6 (PMOD group, Switzerland). Statistical analyses were
performed using GraphPad Prism, ver7 (GraphPad Software Inc., La Jolla, CA).
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Labeling MM-DX-929 with chelated 64Cu
Upon receipt of

64CuCl , 64Cu
2

was chelated with 4-DEAP-ATSC (98±2%

chelation efficiency), followed by loading into empty liposome (95±3% loading
efficiency). Briefly, 64CuCl2 was vortexed with 4-DEAP-ATSC solution (0.06 mg/ml
chelator in 0.1M citrate buffer, pH 6) at room temperature for 10 seconds, then
allowed to sit for one minute and vortexed again. Efficiency of

64Cu

chelation was

determined by diluting a sample in citrate buffer for instant thin layer
chromatography as described previously (165). Briefly, the radioactivity at the
solvent front (free

64Cu

in solution) and at the sample origin (64Cu-DEAP-ATSC

complex) was measured by gamma spectroscopy of the iTLC plates. Greater than
90% chelation efficiency was required to proceed to loading.
64Cu-MM-DX-929

was prepared by mixing

64Cu-DEAP-ATSC

with empty

MM-DX-929 liposomes (15 mM phospholipid in 10 mM HEPES buffered saline,
150 mM sodium chloride, pH 6.5) and heated for 10 minutes at 65 °C, followed by
immediate cooling in an ice water bath for one minute, as previously described
(165). Loading efficiency of

64Cu

was assessed by performing size exclusion

chromatography on an Illustra NICK column with a small sample of prepared 64CuMM-DX-929 in HEPES buffered saline (HBS). Radioactivity of the eluent
containing labeled

64Cu-MM-DX-929

in HBS, and the column containing

64Cu-

DEAP-ATSC was measured with gamma scintigraphy. Greater than 90% labeling
efficiency was achieved before proceeding with animal imaging.
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Cell Culture
HT-29 human colorectal adenocarcinoma cells were cultured in McCoy’s 5a
Modified Medium supplemented with 5% fetal bovine serum and 1%
penicillin/streptomycin, as described by ATCC. Cells were kept at 37°C with 5%
CO2 and were passaged with trypsin at approximately 80% confluence. Prior to
inoculation in mice, cells were not passaged more than ten times in culture. Cell
line identity was authenticated at time of all studies with the PowerPlex 16
System from Promega (Madison, WI) in the Applied Genomics Technology Center
at Wayne State University. Analyses were performed using ATCC and DSMZ
reported karyotypes. Tumor fragments were subcutaneously implanted into SCID
NCr female mice on day 0 by trochar.
Animal Studies
Tumor model: Cultured HT-29 human colorectal adenocarcinoma cells were used
to establish a subcutaneous tumor model in female SCID NCr mice (Charles River
Labs; MA) and thereafter maintained in serial passage.
MicroPET studies: Schematic representation of mouse study design is presented
in Figure 1.

Tumors were upstaged to 250mg (range: 200-300mg, day 12), and

mice non-selectively randomized into their respective control (No Rx) and
treatment groups (bev). All mice were imaged with microPET before and after bev
treatment (on days 13 and 20) 24hr after intravenous (IV) administration of 64CuCl2
MM-DX-929. Scans were compared for changes in LP accumulation during this
time period. Mice were euthanized under anesthesia with whole blood and tissues
collected after the second PET for biodistribution measurements and histological
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analysis.

For subsequent studies, after the 2 nd scan, mice were further divided

into 4 groups of n=6 (No Rx, Bev, LP-I, and Bev + LP-I) to assess tumor
progression post bev treatment, with or without LP-I, compared to untreated
controls. All mice were weighed and observed daily for the duration of the study.
Tumors were measured by caliper 2-3x/weekly with the formula [volume (mg) =
length (mm) x width2 (mm2)/2] used to calculate tumor mass.
Tracer

preparation

and

injection:

Empty

LP

Pharmaceuticals, Cambridge, MA) were labeled with

MM-DX-929
64CuCl
2

(Merrimack

chelated with 4-

DEAP-ATSC). Mice were administered 200-300 µCi/injection, IV within a 0.1 to
0.3 ml volume range; 22-24 hours prior to each microPET scan.
Drug preparation: Bevacizumab was prepped fresh for each injection from 25
mg/ml stock diluted with 0.9% sterile saline, pH 6.0 and injected intraperitoneally
(IP) at 5 mg/kg in a volume of 0.2ml/20g mouse on days 14 and 17 (2q7d).
Liposomal Irinotecan (LP-I; MM-398; Onivyde®, Merrimack, Cambridge, MA) was
prepped fresh for each injection from 5.05mg/ml stock diluted with 0.9% sterile
saline, pH 6.0 and injected IV at 10 mg/kg in a volume of 0.2 ml/20g mouse on
days 21, 24, and 28.
All animal studies were approved by and performed in strict accordance with the
policies of the Institutional Animal Care and Use Committee (IACUC) at Wayne
State University.
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Figure 1. Liposome animal study design. Schematic representation of
treatment groups and timeline for mice treated with bev, LP-I, bev followed by LPI, and controls.
Animal Imaging with 64Cu-MM-DX-929 PET
64Cu-MM-DX-929

(104 nm) was used to approximate the systemic

distribution of LP-I (110 nm), as it has been shown to predict the accumulation of
LP-I in solid tumors (166). Following
approximately 200-300 µCi of
via the tail vein.

64Cu-liposome

64Cu-MM-DX-929

64Cu-MM-DX-929

preparation, mice received

(20 μmol/kg lipid) intravenously

was imaged with PET 24±2 hours post-injection,

as liposomes remain in the blood pool for extended periods before depositing in
tissues. Anesthesia was induced with 3% inhaled isoflurane, and maintained
during scanning with 2% isoflurane. Mice were positioned prone on the scanner
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bed with heating pad to maintain body temperature. Fiducial markers labeled with
64Cu

were fixed to the bed for subsequent alignment of PET and CT images. PET

acquisition was performed for 10 minutes, followed by CT scanning 10 minutes to
obtain anatomical images.
Attenuation correction was performed on the whole body microPET images
based on previously recorded transmission scans. Images were reconstructed by
applying an iterative ordered-subsets expectation maximization 2-dimensional
algorithm (167). Together with scatter correction, these parameters yielded an
isotropic spatial resolution of approximately 2mm in full width at half maximum
(168). Prior to study, a phantom for

64Cu

was scanned to calculate conversion

from counts/pixel/minute to kBq(μCi)/cm3.
PET/CT image registration and analysis
PET and CT images were registered and aligned using the PMOD Image
Matching and Fusion Tool. Regions of interest (ROIs) were defined manually on
individual planes of the PET, using the aligned CT images for anatomical
reference. 3-dimensional volumes of interest (VOIs) were generated from the
stacked ROIs of the tissue of interest. Activity in the VOIs, as detected by PET in
kBq(μCi)/cm3, was converted to standardized uptake values based on injected
dose and body weight. SUVmax values were calculated by averaging the max pixel
value in the ROI of the three hottest consecutive planes in a tissue, and normalizing
to injected dose and body weight.
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64Cu-MM-DX-929

PET imaging of short-term bev effects

A baseline 64Cu-MM-DX-929 PET was performed on all mice at day 14 posttumor implant, followed by half of the mice receiving two injections of bev over
seven days. Bev was administered IP at 5 mg/kg in a single injection performed
on days 14 and 17 (two total injections). All mice received a second 64Cu-MM-DX929 PET on day 20. Day 20 scans (post-treatment) were compared to scans from
day 13 (baseline) and analyzed for changes in 64Cu-MM-DX-929 delivery to tumor.
Results were compared between bev-treated and control mice.
Whole body tissue distribution of 64Cu-MM-DX-929
64Cu-MM-DX-929

retention in bulk tissues was assessed by gamma

spectroscopy of resected tissues. Briefly, following the second PET scan (day 7),
mice were sacrificed and tissues harvested (n=8). These included tumor, liver,
heart, lung, intestine, stomach, kidney, spleen, and blood. Tissues were washed
in water, weighed, and activity was measured for one minute on a gamma counter.
Activity in tissues was decay corrected to time of injection and normalized to tissue
weight (kBq/cc). Tissue biodistribution was compared between bev-treated and
untreated mice to ensure that bev treatment was not affecting retention of

64Cu-

MM-DX-929 in healthy tissues.
Immunohistochemistry and microvessel density analysis
Tumors resected after the second PET were fixed in formalin and paraffin
embedded.

Immunohistochemistry for CD34, and staining with hematoxylin

(Sigma Aldrich, St. Louis, MO) was performed on 5 µm slices, and digital images
of the entire cross section were captured. Sample identities were blinded, and

32

images were analyzed with Pannoramic Viewer ver1.15.4 (3DHISTECH Ltd.,
Budapest, Hungary). For each tissue, five distinct areas of 200 mm2 were utilized
in assessing microvessel density. Briefly, tumor blood vessels (as identified by
CD34 staining) were counted in each section, and distance measurements across
the widest diameter of each vessel were used to determine vessel size. The
average number of vessels per cm3 and the average vessel diameter were
calculated.
64Cu-labeled

liposome interactions with macrophage populations in blood

64Cu-MM-DX-929

as well as

64Cu-MM-302,

a structurally related liposome,

were incubated in human whole blood for one hour with gentle rocking at 37˚C.
Incubated blood samples, as well as samples collected from clinical trials of
patients scanned with

64Cu-MM-302,

were subjected to density gradient

centrifugation over a Ficoll-Hypaque gradient. Plasma, white blood cells, and red
blood cells (RBCs) were separated via multiple centrifugation steps. White blood
cell fractions were incubated in cell culture flasks with lymphocyte-cultured medium
for 3 hours to induce macrophage adherence. Non-adhered lymphocytes were
carefully aspirated, and attached monocytes were collected via Trypsin wash.
Plasma, RBC, lymphocyte, and macrophage fractions were measured with gamma
scintigraphy to determine

64Cu-LP

content. Values are represented as %total

counts.
Whole blood from patients receiving

64Cu-MM-302

was also subjected to

size exclusion chromatography to determine LP stability at multiple time points,
including 1 hour, 24 hours, and 48 hours after injection.
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Statistical Analysis
Tumor growth curves with mean ± standard error was plotted and growth
rates were tested with linear mixed model. Tumor latency to 1 gram total burden
was tested with Kruskal-Wallis test, after normality assumption was evaluated with
Shapiro-Wilk test. Statistical analyses were performed using R version 3.2 (The R
Foundation for Statistical Computing). All other statistical analyses were performed
using GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA). Data were
presented as the mean ± standard error. Comparisons between the bevacizumab
and control were performed using two-sample Student’s t-test. A p-value of <0.05
was considered statistically significant.
3. Results
3.1.

64Cu-MM-DX-929

PET can detect significant differences in LP delivery
between colon tumors treated with bev and untreated controls
Liposome distribution in mice bearing subcutaneous HT-29 colon tumor

xenografts was measured with

64Cu-MM-DX-929

PET at baseline prior to any

treatment. Due to the extended circulation times of liposomes in the body, images
were acquired 24 ± 2 hours following tracer injection (approximately two half-lives
of 64Cu, t1/2 = 12.7 hours) to allow extravasation from the blood pool (165). Tracer
uptake was notable in liver (due to extensive vasculature) and spleen, and was still
visible in the heart (residual blood pool). Tumors were easily detectable with 64CuMM-DX-929 PET, with relatively ubiquitous tracer distribution at baseline.
By measuring changes in tumor SUVmax between baseline and posttreatment scans (%ΔSUVmax) we found the difference in %ΔSUVmax of bev-treated
tumors compared the controls to be statistically significant, p=0.0002 (Figure 2).
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This trend was seen when comparing mice (data analyzed as an averaged value
of both tumors per mouse), but was also true when comparing individual tumors
(Figure 3). Scans from two control mice were determined to be un-evaluable due
to technical issues with one or both PET images for those mice. Changes in 64CuMM-DX-929 PET from baseline to post-treatment were noticeably different
between tumors treated with bev and untreated controls. Tumors in control mice
showed increased

64Cu-MM-DX-929

baseline images (Figure 4).

retention after seven days compared to

Although these tumors often continued to grow

between baseline and subsequent scans, increases in

64Cu-MM-DX-929

tumor

accumulation was independent of individual tumor size or growth rate (data not
shown). In mice treated with bev, however,

64Cu-MM-DX-929

delivery to tumor

tissues appeared to remain stable between baseline and post-treatment scans
(Figure 5). Again, these trends were independent of tumor size or growth rate
(data not shown).
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Figure 2. Changes in SUVmax of HT-29 colon tumors decreased after
treatment with bev compared to untreated tumors. %ΔSUVmax of liposome
accumulation in tumor tissues of mice which received no treatment (n=10),
compared to mice treated with two doses of bev (n=12) as measured by 64Cu-MMDX-929 PET. %ΔSUVmax values represent the average %ΔSUVmax of both tumors
Change in SUVmax of HT-29 Colon tumors
within an individual mouse. (***p=0.0002)
Table Analyzed

after one week treatment with bevacizumab
CUMULATIVE

***

%Change SUVmax

150
100

Column B
vs.
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vs.
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Unpaired t test
P value
P value summary
Significantly different (P < 0.05)?
One- or two-tailed P value?

0.0003
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Two-tailed
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How big is the difference?
Mean ± SEM of column A
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Difference between means
95% confidence interval
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Figure 3. SUVmax of individual tumors decreased after treatment with bev
compared to untreated tumors. Change in SUVmax values measured in individual
HT-29 tumor xenografts after two injections of bev compared to untreated tumors.
(p=0.0003)

t=3.78 df=69

-2.93 ± 4.594,
28.93 ± 7.235,
31.86 ± 8.428
15.04 to 48.67
0.1715

2.279, 33, 36
0.0170
*
Yes
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Figure 4. 64Cu-MM-DX-929 delivery to HT-29 colon tumor xenografts
increases after 7 days without therapeutic intervention. 64Cu-MM-DX-929
scans of a mouse bearing two subcutaneous HT-29 colon xenografts (outlined) at
baseline (A) and after seven days with no treatment (B). Images are coronal slices
of the mouse midsection with fused PET/CT, PET alone, and CT alone. PET
images were scaled from ½ background (kBq/cc) to liver average (kBq/cc)
calculated based on average values from both scans.
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Figure 5. 64Cu-MM-DX-929 delivery to HT-29 colon tumor xenografts does
not increase when treated with two doses of bevacizumab. 64Cu-MM-DX-929
scans of a mouse bearing two subcutaneous HT-29 colon xenografts (outlined) at
baseline (A) and after seven days of bev treatment (B). Images are coronal slices
of the mouse midsection with fused PET/CT, PET alone, and CT alone. PET
images were scaled from ½ background (kBq/cc) to liver average (kBq/cc)
calculated based on average values from both scans.
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Interestingly,

64Cu-MM-DX-929

PET scans visualized more frequent and

dramatic shifts in the volumetric distribution of tracer across the mass of tumors
treated with bev. This suggests that early into treatment, prior to measurable
morphological differences,

64Cu-MM-DX-929

PET identified altered tumor

vascularity in bev-treated tumors, as well as early effects of bev on LP distribution.
64Cu-MM-DX-929

PET images suggest that the early effects of bev may

substantially alter or limit LP penetration into tumor tissues. Additionally, changes
in tracer deposition in individual tumors were more highly variable in bev-treated
tumors, while control tumors often exhibited similar increases in uptake over time
(Figure 6). Taken together,

64Cu-MM-DX-929

PET was able to detect increased

LP accumulation/delivery in colon tumor xenografts tended to increase as tumors
progressed without intervention, but this trend was reduced or abolished with only
two doses of bev. Thus, with 64Cu-MM-DX-929 PET we were able to measure the
effects of bev therapy on LP delivery to solid tumors early into treatment.
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Figure 6. Changes in HT-29 tumor SUVmax values measured with 64Cu-MMDX-929 PET. Lines represent SUVmax values for individual tumors in mice treated
with bev (A) or tumors in untreated mice (B).
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3.2. Bevacizumab does not alter systemic distribution of 64Cu-MM-DX-929 in
non-tumor tissues
Any treatment with the potential to alter systemic distribution of a PET tracer
could confound image analysis and uptake quantitation. To verify that bev did not
significantly alter

64Cu-MM-DX-929

global uptake in tissues, activity in normal

tissues (resected immediately following the second PET of selected mice) was
measure by gamma spectroscopy and compared between treated and untreated
mice. No significant differences were detected between normal tissues of bevtreated mice and control mice (Figure 7).

This demonstrates that systemic

distribution was not altered in a way which would be confounding for image
analysis in tissues of interest.
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Figure 7. Bev treatment did not change overall biodistribution of 64Cu-MMDX-929. %injected radioactive dose per gram of resected tissues was measured
directly after the second 64Cu-MM-DX-929 PET scan.

42

3.3. Colon tumor growth was delayed by short-term bev alone, liposomal
irinotecan alone, or short-term bev followed by liposomal irinotecan
Following the second

64Cu-MM-DX-929

PET, bev-treated mice and

untreated mice were further randomized into the following subsets: (1) untreated
controls (n=6); (2) short-term bev (2q7d) only (n=6); (3) LP-I only (n=6); (4) shortterm bev followed by LP-I (n=6) (Figure 1). One mouse assigned to receive LP-I
only (group 3) was not included in data assessments due to lack of drug availability
at the time of study. Mice were treated and tumor progression was monitored until
tumor burden or weight loss warranted euthanasia. Tumor growth was considered
individually, as well as by per-mouse analysis of total tumor burden.
As expected, HT-29 tumors in mice which received no treatment exhibited
unrestrained growth (Figure 8A). Treatment with two doses of bev resulted in a
measurable but modest delay in tumor progression compared to controls.
Interestingly, tumors in mice treated with LP-I also exhibited delayed growth
compared to controls, despite being administered later than bev, at advanced
stage of disease.

Succeeding short-term bev with LP-I demonstrated tumor

inhibition compared to untreated controls, although there was no notable
therapeutic advantage to this combination compared to bev or liposomal irinotecan
alone with the specific doses and regimens tested.
As was seen in the PET scans with bev, individual tumor and mouse
responses varied in each of the treatment groups. Spaghetti plots of tumor burden
in individual mice show that while untreated tumors progressed similarly quickly,
each treatment regimen yielded variable rates of response in individuals (Figure
8Ca-d). Tumor growth rates and drug-induced growth inhibition were independent
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of tumor size at treatment initiation (data not shown). When measuring tumor
latency to 1 gram total burden per mouse, each treatment group shows increased
latency compared to untreated controls, though the differences in group medians
were not statistically significant (Figure 8B).
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Figure 8. HT-29 tumor growth is affected by bev, LP-I, and bev followed by
LP-I compared to untreated controls. Tumor growth inhibition assessed by
caliper measurements represented for each treatment group compared to control,
represented as a mixed linear model (****p<0.0001) (A). Tumor latency to
approximately 1 gram total tumor burden was assessed for individual mice as a
measure of growth delay due to treatment (B). Spaghetti plots of tumor growth in
individual mice according to treatment with bev (C.b), LP-I (C.c), or bev followed
by LP-I (C.d) compared to control tumors (C.a). Bev administration is indicated by
red lines, LP-I administration is indicated by blue lines.
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3.4. Bev treatment induced measurable changes in tumor blood vessels
after two injections
Although treated mice received only two injections of bev, HT-29 tumors
resected after the second

64Cu-MM-DX-929/PET

showed early evidence of bev

response. Microvessel density (MVD) was assessed via immunohistochemical
staining for CD34, followed by blinded analysis of tissues for vessel number and
average diameter. CD34 staining revealed notable differences in vessel size
between bev-treated and control tumors (Figure 9A). Short-term bev resulted in
significantly smaller vessel diameters compared to untreated controls (Figure 9B).
The total tissue area occupied by CD34+ vessels in treated tumors was 3.8% ±
1.5% compared to 5.7% ± 1.7% in control tumors (p=0.04, Figure 10). This
indicates that

64Cu-MM-DX-929

in the blood pool has a very small contribution to

the tumor tracer activity. While the size of the vessels was noticeably altered
following bev, the vessel density (vessels/cm3) showed no measurable difference
between bev-treated and untreated tumors (Figure 9C). These data would indicate
that two injections of bev had begun eliciting an anti-vascular effect, and that the
second

64Cu-MM-DX-929

PET was performed during the early stages of bev

response. Taken together with trends seen in PET, these data show that

64Cu-

MM-DX-929 PET was able to measure changes in LP delivery which were likely
due to the early effects of bev. Importantly, while bev-induced changes in vessel
diameter were measurable at the time of the second PET, no difference was seen
in tumor growth rates between treated and control mice (Figure 8A). Thus,

64Cu-

MM-DX-929 PET was able to measure early fluctuations in LP delivery due to antivascular therapy, prior to any quantifiable changes to tumor morphology.
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Figure 9. Bev induced significant changes in blood vessel diameter early
into treatment. 20X images of HT-29 tumor tissues stained with CD34 to identify
blood vessels (brown) and hematoxylin to denote cell nuclei (blue) show significant
differences in vessel size between untreated controls (A. a-c) and tumors treated
with bevacizumab (A. d-f). Microvessel density analysis of blood vessel diameter
in bev-treated tumors compared to untreated controls (B). Vessel density (vessels
per cm3) was compared between treated and untreated tumors (C). Data are
presented as mean ± SD. **p=0.0042
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Figure 10. Percentage of total tissue area occupied by CD34 positive vessels
in untreated and bev treated tumors. CD34 positive vessels were identified and
2
diameters measured over a total of 1 cm of tumor. Total vascular space per
sample was determined by summation of the areas occupied by each vessel, as a
percentage of total surveyed area. This can be represented as A vasc =
2

2

(Σ[π*(d/2) ]1 n)/cm .
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3.5.

64Cu-LP

do not associate with macrophages and are stable in circulation
for up to 48 hours.
In certain instances, macrophages have been found to take up NP such as

liposomes (169).

When utilizing LP for imaging, significant macrophage

engulfment of tracer-LP can confound image interpretation. To determine the
probability of macrophage interference with
we measured macrophage uptake of
LP under clinical investigation,

64Cu-MM-DX-929

64Cu-MM-DX-929

64Cu-MM-302,

for PET in patients,

and a structurally related

in human whole blood. Following

incubation with either labeled liposome for 1 hour, blood cell populations were
measured for radioactivity (Table 3). Radioactivity remained in the plasma, with
little to no activity associated with monocyte populations. The same results were
found when analyzing
64Cu-MM-302

64Cu-MM-302

in blood samples from patients receiving

PET (representative patient #300-1055 presented in Table 3). Blood

samples taken at 1, 24, and 48 hours demonstrated that activity remained in the
plasma for at least 48 hours (representative patient #300-1055; Figure 11A).
HPLC analysis of LP stability was performed following

64Cu-MM-302

injection in

patients, which demonstrated that activity remains within LP for at least 48 hours
(representative patient #300-1055; Figure 11B). Thus,

64Cu-MM-302

and remained in the plasma for at least 48 hours, suggesting that

was stable

64Cu-LP

PET at

24 hours (or later) should not confounded by free 64Cu or macrophage engulfment
of LP.
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Table 3. %64Cu-LP activity in human whole blood associated with blood cell
populations.

Figure 11. 64Cu-LP are stable in circulation and remain in plasma for at least
48 hours. Radioactivity in blood cell populations was assessed in patients who
received 64Cu-MM-302 PET at time 0, 1, 24, and 48 hours. Data from a
representative patient (#300-1055) is shown. Activity in blood fractions is plotted
compared for each time point compared to whole blood (A), and HPLC analysis of
64Cu association with LP is shown at 48 hours post-injection (B) (previously
published in (170)).

50

4. Discussion
The urgent need for precision medicine for CRC is not limited to the
development of more sophisticated therapies, but also techniques to predict and
monitor therapeutic efficacy. Here we have demonstrated the utility of a dynamic
system using 64Cu-labeled liposomes for PET to non-invasively measure the early
effects of bev therapy on LP delivery to colon tumor xenografts in mice.
Furthermore, significant differences measured with

64Cu-MM-DX-929

PET

between bev-treated and control tumors provided early insight into therapeutic
outcomes in mice subsequently treated with liposomal irinotecan.
Clinically, the potential advantages of LP are twofold: (1) sustained and/or
local delivery of drugs or drug combinations to tumor tissues, and (2) reduced
toxicity profiles as normal tissues are shielded from toxic drugs (45, 171-174).
However, heterogeneous, inconsistent, or obstructed delivery of

these

nanoparticles to tumor tissues can hamper their effectiveness, and is hypothesized
to be a contributor to the lack of clinical success seen with many LP. Passive
targeting through EPR relies on specific properties of tumor blood vessels, which
are constantly changing in response to the tumor environment and therapeutic
intervention, particularly with antivascular agents. While antivascular agents are
expected to disrupt tumor vessels, there is some evidence suggesting that early
effects of bev treatment may transiently “normalize” tumor vessels, though these
effects are not consistent (164, 175-177).

Thus, a non-invasive means of

measuring LP delivery to tumor tissues could provide individualized information on

51

the effect of drugs like bev on LP delivery and subsequent efficacy (17, 165, 170,
178).
In these studies, we found that we could use PET to quantify changes in LP
accumulation in colon tumor xenografts very early into bev treatment. In mice that
received no treatment in between PET scans,

64Cu-MM-DX-929

accumulation in

tumors increased, indicating that LP-I were still able to reach and penetrate HT-29
tumor tissues and elicit an effect. While previous studies of LP-I in HT-29 tumors
demonstrated significant anti-tumor effects when administered earlier into tumor
progression (179, 180), the modest effects seen here were likely attributed to
treatment initiation at late-stage disease. Because of this, we anticipated no
significant difference in survival among the treatment groups. After two injections
over the course of one week, bev had already begun eliciting anti-vascular effects,
which were quantifiable with

64Cu-MM-DX-929

PET.

While bev treatment

conferred therapeutic advantage in HT-29 tumors, 64Cu-MM-DX-929 PET showed
that even short-term bev treatment began to impede liposome delivery and
penetration. This observation is consistent with the lack of therapeutic benefit seen
in treating mice with LP-I which had already received bev.
In the clinic, bev and other antivascular agents, such as ziv-aflibercept
(Zaltrap; Regenron Pharmaceuticals Inc., Tarrytown, NY), are approved to treat
patients with CRC.

As liposome-based therapies are introduced for this

population, understanding the effects of antivascular agents on LP delivery could
reduce the probability of employing incompatible drug combinations. Furthermore,
when designing clinical trials of LP-drug platforms for colon cancer, imaging
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techniques could be used to non-invasively monitor changes in LP delivery over
time, or as a result of various therapies.
Along with the clinical implications of bev and LP-therapy in CRC patients,
we have been able to employ a powerful model for dynamically assessing
modulation of LP delivery.

64Cu-MM-DX-929

PET was able to non-invasively

quantify the effects of bev on LP delivery, which likely affected subsequent therapy
with liposomal irinotecan injection. This would suggest that 64Cu-MM-DX-929 PET
may be sensitive enough to detect and monitor changes in LP delivery to solid
tumors which may directly influence therapeutic LP efficacy. Aspects of the tumor
environment which affect LP distribution are dynamic, and are certain to vary
among patient populations. Thus, predicting and monitoring LP delivery with a
non-invasive theranostic imaging is an invaluable tool in achieving precision
medicine with LP for CRC patients.
Finally, the mission of individualized treatment plans for patients with cancer
is one that requires a significant preclinical effort to identify diagnostic and
therapeutic strategies. In this study, we have demonstrated a practical system for
measuring therapeutic modulation of LP delivery that predicted and described
subsequent therapeutic results.

64Cu-MM-DX-929

PET may be used in preclinical

studies of therapeutic LP to efficiently measure the effect of combination therapies,
treatment timelines/conditions, etc. on LP delivery. Utilizing imaging protocols with
tracer LP like

64Cu-MM-DX-929

can quickly and non-invasively identify treatment

conditions which improve or hinder LP delivery. In CRC, this could mean creating
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more avenues towards precision medicine with liposomes to improve outcomes
for patients.
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CHAPTER 3. 18F-FMAU PET TO EVALUATE RESPONSE TO CISPLATIN IN
PRE-CLINICAL LUNG CANCER STUDIES
1. Introduction
With the success of

18F-FLT

PET in oncological imaging, a variety of

radiolabeled thymidine analogues have been synthesized for assessment in
imaging studies (103). Among these,
18F-FLT

18F-FMAU

is of particular interest. While

lacks the 3’ hydroxyl group on natural thymidine causing termination of

DNA strand elongation,

18F-FMAU

maintains a 3’ hydroxyl group and can be
18F-FMAU

for PET

suggested that FMAU had lower uptake in bone marrow compared to

18F-FLT

incorporated into DNA (106). Early research into the utility of

(110). In multiple tumor types, metastases to the bone are common, and would
be easier to identify in scans with a tracer that demonstrates lower background in
the marrow. Thus, 18F-FMAU was studied as a potential alternative to 18F-FLT for
PET of cellular proliferation in oncology (181, 182).
Natural thymidine is incorporated into dividing cells through the DNA
salvage pathway (183). After cellular uptake, thymidine molecules (as well as
functional analogues) undergo phosphorylation by thymidine kinases, which
prevents transport out of the cell. Two forms of thymidine kinases are present in
human cells, namely thymidine kinase 1 (TK1) and thymidine kinase 2 (TK2) (184).
TK1 is primarily located in the cytoplasm, and its activity is strongly associated with
the S phase of the cell cycle during nuclear DNA synthesis (185). Conversely,
TK2 activity is relatively low and ubiquitous compared to TK1, and TK2 is closely
associated with mitochondrial DNA synthesis (186).

In vitro studies have

demonstrated that FLT is predominantly phosphorylated by TK1, with strong

55

retention in actively dividing cell populations (187).

Conversely, FMAU is

predominantly phosphorylated by TK2, and is not as highly retained as FLT in
proliferative tissues (102). Thus, while

18F-FLT

PET is considered a means of

measuring tumor proliferation, 18F-FMAU PET may offer a different perspective on
cancer cell metabolism.
Mitochondrial metabolism, a critical determinant of cellular energy
production, is often dramatically altered in tumor cells. Further, dynamic and
transient shifts in mitochondrial biochemistry are being investigated as biomarkers
for understanding tumor ATP synthesis, fatty acid oxidation, apoptosis signaling,
synthesis of nucleotides, and more (188-190). Heterogeneity of mitochondrial
biology in human tumors complicates the use of mitochondrial metabolism as a
biomarker for cancer (191).

However, measuring mitochondrial changes that

result from treatment could provide insight into therapeutic effects on tumor
metabolism (192, 193). It is conceivable that, while
choice for measuring proliferation with PET,

18F-FMAU

18F-FMAU

is a less attractive

PET may be useful in

measuring mitochondria-related effects in tumors.
Previous work in our lab, performed by Tehrani et al., provided evidence
that FMAU uptake in tumor cells may be associated with cell stress (102).
Following exposure to nutritional stress, prostrate and breast cancer cell lines
exhibited increased FMAU retention while FLT retention and TK1 activity
decreased. FMAU retention was also increased in cells exposed to oxidative and
reductive stresses, and correlated with mitochondrial mass measured in the cells.
These data provide rationale for the study of

18F-FMAU

PET as a measure of
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cellular stress, particularly energy metabolism stress which occurs early into
treatment. We chose to measure the early effects of cisplatin treatment in human
lung tumor models with 18F-FMAU PET.
2. Materials and Methods
Materials
NCI-H460 cells, NCI-H292 cells, and Roswell Park Memorial Institute
(RPMI)-1640 medium were purchased from ATCC (Manassas, VA) and kept below
15 passages following receipt.

For in vitro studies with cisplatin, cis-

Diammineplatinum(II) dichloride was purchased form Sigma Aldrich (St. Louis,
MO). HPLC analysis of blood samples was performed using Hypersil C18 columns
(Thermo Fisher Scientific, Waltham, MA). Gamma spectroscopy measurements
were acquired with a Packard Cobra II gamma counter (Perkin-Elmer Inc.,
Waltham, MA). An R4 microPET (Concorde Microsystems, Knoxville, TN) was
used for all animal PET scan acquisition. PMOD Image Matching and Fusion Tool
ver3.6 (PMOD group, Switzerland) was utilized for image registration, matching,
and analysis. Statistical analyses were performed using GraphPad Prism, ver7
(GraphPad Software Inc., La Jolla, CA).
Cell Culture
H460 large cell lung carcinoma cells and H292 mucoepidermoid pulmonary
carcinoma cells cultured in RPMI-1640 medium supplemented with 5% fetal bovine
serum and 1% penicillin/streptomycin, as described by ATCC. Cells were kept at
37°C with 5% CO2 and were passaged with trypsin when cells reached
approximately 80% confluence.

Prior to inoculation in mice, cells were not
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passaged more than ten times in culture. Cell line identity was authenticated at
time of all studies with the PowerPlex 16 System from Promega (Madison, WI)
in the Applied Genomics Technology Center at Wayne State University. Analyses
were performed using ATCC and DSMZ reported short tandom repeat loci for the
cell lines.
Cell Line Sensitivity to Cisplatin
In order to establish the difference in cisplatin sensitivity between H460 and
H292 cells, 5 day MTT assays were performed to determine IC50 values. Cisplatin
(cis-Diammineplatinum(II) dichloride) was dissolved in sterile PBS and sonicated
for 30 minutes at 37˚C until dissolved prior to generating series dilutions in culture
medium. Cisplatin concentrations which resulted in a 50% loss of cell viability (IC50)
after 5 days was determined independently for each cell line.

These

concentrations of cisplatin were used for all in vitro tracer uptake assays.
18F-FMAU

Uptake in Cells Treated With Cisplatin

H460 and H292 cells were seeded in 6-well plates (900,000 and 1.8 million,
respectively, due to doubling time). Cells were allowed to reach approximately
50% confluency (exponential growth phase) under normal culture conditions. Cells
were exposed to IC50 concentrations of cisplatin (as determined by 5-day MTT) or
vehicle (PBS) in complete culture medium for 24 hours. Following treatment, drugor vehicle-containing medium was removed and cells were exposed to

18F-FMAU

in medium for 1 hour (approximately 0.05 uCi/well), at 37 ˚C and 5% CO 2.

18F-

FMAU medium was carefully collected and cells were washed three times with icecold PBS (between 2-4˚C) to impede any subsequent transmembrane transport or
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tracer phosphorylation, and remove residual free tracer.

Cells were lysed with

1M KOH and collected, and all fractions were measured with gamma scintigraphy.
Cellular uptake of

18F-FMAU

was compared in both cell lines between cisplatin-

and vehicle-treated cells.
Animal Studies
Tumor model: Cultured H460 and H292 cells grown in complete culture medium
were used to establish subcutaneous tumor models in female SCID NCr mice
(Charles River Labs; MA), via suspension in Matrigel prior to inoculation. Tumors
were maintained in serial passage, via inoculation with H460 or H292 tumor
fragments subcutaneously by trochar, over the course of experiments. All imaging
studies were performed within 5 tumor passages in mice.
MicroPET studies: Schematic representation of mouse study design is presented
in (Figure 12). Tumors were allowed to grow until they we approximately 250mg
(range: 200-300mg) based on the growth rates of each tumor type. Animals were
randomized into their respective control (No Rx) and treatment groups (cisplatin).
All mice were imaged with microPET before and 24±2 hours after a single injection
of cisplatin. Scans were compared for changes in tracer uptake in tissues of
interest. Mice were euthanized under anesthesia with whole blood and tissues
collected after the second PET for HPLC analysis and biodistribution
measurements, respectively.

All mice were weighed and observed daily for the

duration of the study. Tumors were measured by caliper 2-3x/weekly with the
formula [volume (mg) = length (mm) x width2 (mm2)/2] used to calculate tumor
mass.
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Tracer preparation and injection:

18F-FMAU

was synthesized as described

previously (103). To achieve similar injected activity and volume,
diluted in sterile saline when necessary.

18F-FMAU

was

Mice were administered 200-300

uCi/injection intravenously (IV) within a 0.1 to 0.3 ml volume range.
Drug preparation: Cisplatin was freshly prepared for each injection from stock
diluted with 0.9% sterile saline, pH 6.0 and injected IV at 11 mg/kg in a volume of
approximately 0.2ml/20g mouse.

Cisplatin injections were administered

immediately following the first PET scan, after the mouse had fully recovered from
anesthesia. Cisplatin treatment consisted solely of a single injection, and effects
were assessed via PET after 24 ± 2 hours.
All animal studies were approved by and performed in strict accordance with the
policies of the Institutional Animal Care and Use Committee (IACUC) at Wayne
State University.
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Figure 12. Schematic representation of FMAU mouse study design. Mice
bearing H460 or H292 tumors were randomized to treatment groups, with half of
the mice receiving IV cisplatin following the first PET. All mice were scanned again,
approximately 24 hours after the first PET.
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Animal Imaging with 18F-FMAU PET
Following receipt of 18F-FMAU mice received approximately 200-300 µCi of
18F-FMAU

intravenously via the tail vein. Whole body PET images were acquired

one hour after IV administration of

18F-FMAU.

Dynamic images of representative

animals from each treatment group were acquired immediately after tracer
injection for 60 minutes, followed by a 10 minute whole body scan. Anesthesia for
image acquisition was induced with 3% inhaled isoflurane prior to placement on
the scanner, and maintained during scanning with 2% isoflurane. Mice were
imaged in a prone position on the scanner bed with heating to maintain body
temperature.
Attenuation correction based on routine transmission scans was performed
on the whole body microPET images. Images were reconstructed by applying an
iterative ordered-subsets expectation maximization 2-dimensional algorithm (167)
and corrected for scatter. These parameters yield an isotropic spatial resolution
of approximately 2mm in full width at half maximum (168). Prior to study, a
phantom for

18F

was scanned to calculate conversion from counts/pixel/minute to

kBq(μCi)/cm3.
PET/CT Image Registration and Analysis
PET and CT images were registered and aligned using the PMOD Image
Matching and Fusion Tool ver3.6 (PMOD group, Switzerland). Regions of interest
(ROIs) were defined manually on individual planes of the PET. 3-dimensional
volumes of interest (VOIs) were generated from the stacked ROIs of the tissue of
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interest. Activity in the VOIs, as detected by PET in kBq(μCi)/cm3, as well as
injected dose and body weight were used to calculate standardized uptake values
(SUV). SUVmax values were determined by averaging the max pixel value within
each of the three hottest consecutive ROIs of a tissue, and normalizing to injected
dose and body weight.
Whole Body Tissue Distribution of 18F-FMAU
18F-FMAU

retention in resected tissues was assessed by gamma

spectroscopy. Briefly, following the second PET scan, mice were sacrificed and
tissues harvested. Resected tissues included tumor, liver, heart, lung, intestine,
stomach, kidney, spleen, and whole blood.

Serum from whole blood of

representative animals of each treatment group was subjected to HPLC analysis.
Tissues were washed, weighed, and activity was measured for one minute on a
gamma counter. Activity in tissues was decay corrected to time of injection and
normalized to tissue weight (kBq/cc). Activity per gram of tissue was calculated
based on the injected dose of

18F-FMAU.

Tissue biodistribution was compared

between mice treated with cisplatin and untreated controls to ensure that cisplatin
treatment was not affecting systemic distribution or retention of

18F-FMAU.

HPLC of Circulating 18F-FMAU in Whole Blood
Following the second 18F-FMAU PET, whole blood was drawn from animals
post-sacrifice to determine if

18F-FMAU

had been metabolized during circulation

time. Samples representing treated animals and untreated controls were selected
for HPLC analysis of

18F-FMAU,

as previously described (102). Briefly, sera

collected from whole blood was loaded onto a Hypersil C18 column with 6%
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Acetonitrile, 10mM NaOAc, and allowed to run at a flow rate of 1 ml per minute.
0.5 ml fractions were collected and

18F

activity was measured via gamma

scintigraphy. Curves generated from the HPLC of blood samples were compared
to results from running a small aliquot of pure

18F-FMAU

as received prior to

injection.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 7 (GraphPad
Software Inc., La Jolla, CA). Data are presented as the mean ± standard deviation,
unless otherwise stated. Comparisons of PET SUV data were performed using
two-sample Student’s t-test. A p-value of <0.05 was considered statistically
significant.
3. Results
3.1. Changes in 18F-FMAU uptake in lung tumor cells after cisplatin treatment
differ based on cisplatin sensitivity
To assess the capacity of 18F-FMAU to measure early response to cisplatin
treatment, we sought to compare lung cancer cell lines with differing sensitivities
to cisplatin.

Multiple non-small cell cancer cell lines were subjected to MTT

following treatment with cisplatin to determine relative sensitivity (data not shown).
Of these, H460 cells and H292 cells were selected for further study, as these cells
demonstrated a measurable difference in sensitivity to cisplatin. IC50 values were
determined independently for H460 and H292 cells by exposing the cells to a
series of cisplatin concentrations for 5 days, followed by MTT (Figure 13). H460
cells were identified as being more sensitive to cisplatin treatment (IC50 = 0.06 nM)
than H292 cells (IC50 = 0.2 nM). The determined IC50 values were used throughout
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all of the in vitro studies, representing the concentration of cisplatin which, after 5
days, would result in 50% cell death.

65

Figure 13. H460 cells are more sensitive to cisplatin-induced cell killing than
H292 cells. Assessment of cell viability of H460 and H292 cells was assessed by
MTT after 5 days of exposure to cisplatin concentrations in complete culture
medium. IC50 values were determined as the concentration of cisplatin capable of
causing a 50% loss of viability after 5 days. IC50 values were determined
independently for each cell line, by which H460 cells were determined to be
“cisplatin-sensitive” and H292 cells “cisplatin-resistant”.
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Cellular uptake assays of

18F-FMAU

were performed with H460 and H292

cells following exposure to cisplatin or vehicle (PBS) in complete culture medium.
Cells were treated with determined IC50 concentrations of cisplatin for 24 hours,
and subsequently exposed to cisplatin-free, complete culture medium containing
18F-FMAU

for 1 hour. Following multiple washes, 18F-FMAU retention in cells was

assessed via gamma scintigraphy. Interestingly, little change was noted in

18F-

FMAU retention in sensitive H460 cells following exposure to cisplatin (Figure
14A), while resistant H292 cells demonstrated significantly increased retention
with treatment (Figure 14B). As expected, IC50 concentrations determined with 5
day MTT induced negligible reductions on cell number and viability after 24 hours,
with H460 and H292 cells maintaining 100 ± 2% and 96 ± 2% viability respectively,
as assessed by Trypan Blue measurements (data not shown). This indicates that
differences seen in 18F-FMAU uptake in cells between treated and untreated cells
were not the result of significant differences in viability.
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Figure 14. After 24 hours of cisplatin treatment 18F-FMAU uptake increased
in H292 cells but not H460 cells. Plated cells were exposed to 18F-FMAU for one
hour following 24 hours of cisplatin treatment (at determined IC50 concentrations)
to measure the effect of treatment on tracer retention compared to vehicle controls.
Following washes, cell-associated 18F-FMAU in treated cells was quantified and
normalized to uptake in untreated controls. (****p<0.0001).
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3.2. Significant decreases in 18F-FMAU uptake were observed in H460
xenografts but not H292 xenografts after 24 hours of cisplatin treatment
in mice
Tumor retention of

18F-FMAU

following 24 hours of cisplatin treatment was

assessed in vivo with microPET of female SCID NCr mice bearing H460 or H292
xenografts. Mice were scanned at baseline, prior to any treatment, 1 hour after
injection of

18F-FMAU.

Immediately following the scan, half of the mice in each

tumor group received a single injection of cisplatin at 11 mg/kg. All mice were
scanned again with 18F-FMAU PET 24 ± 2 hours after the baseline scan. Notable
uptake was seen in tumor tissues, as well as in the bladders of some mice,
indicative of clearance.

Low uptake was seen in muscle tissue, which was

selected for background measurements of 18F-FMAU uptake. SUVmax values were
compared between baseline scans and post-treatment scans to generate
%ΔSUVmax values for each individual tumor.
PET images revealed robust changes in 18F-FMAU SUVmax in treated H460
(cisplatin-sensitive) tumors, with a mean change of -40.0% (range of -21.1% to
52.5%). This was statistically significant (****p<0.0001) compared to untreated
H460 tumors, which showed negligible change in SUVmax 24 hours after baseline,
with a mean of 3.73% (range of -7.4% to 12.4%) (Figure 15). Cisplatin-resistant
H292 tumors, on the other hand, showed no significant change in SUVmax between
PET scans, in both treated (mean change of -5.39%, range of -26.1% to 27.7%)
and untreated tumors (mean change of -1.03%, range of -30.6% to 33.0%).
SUVmax data were validated by assessing changes in SUVmean of isocontours
representing the hottest 50% of the tumor max pixel, which demonstrated the same
trends seen with SUVmax. Cisplatin treatment did not induce critical toxicities in
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any treated mice, although constipation was noted in some treated mice during
necropsy after sacrifice on the second scan day.
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Figure 15. Cisplatin-treated H460 tumors in mice showed significant
reductions in 18F-FMAU uptake compared to H292 tumors imaged with PET.
18F-FMAU PET scans were acquired before and after 24 hour treatment with a
single injection of cisplatin in mice bearing H460 or H292 tumor xenografts.
Uptake in tumor tissues was quantified as SUVmax values, and changes in uptake
following the treatment period were calculated as %ΔSUVmax. (****p<0.0001).
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18F-FMAU

PET images of H460 tumors visualized lower tracer uptake 24

hours after a single dose of cisplatin compared to untreated controls (Figure 16).
In nearly all treated H460 tumors, this effect was evident across the entire volume
of the tumor, both in the center of the mass and in the tumor periphery. In
untreated H460 tumors, changes in tracer uptake were negligible to modest (mean
change of -3.73%, range of -7.4% to 12.4%). Often, untreated tumors showed
slight increases in
of

18F-FMAU

18F-FMAU

uptake, but this was considered within the confines

PET reproducibility, as previously described (194). Unlike H460

tumors, PET of

18F-FMAU

uptake in cisplatin-resistant H292 tumors showed no

consistent trend that could discriminate between treated and untreated tumors
(p=0.9850) (Figure 17).
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Figure 16. 18F-FMAU PET scans of mice bearing H460 tumors before and
after cisplatin treatment. Representative 18F-FMAU scans of mice bearing H460
(cisplatin-sensitive) xenografts at baseline (left) and after 24 hours (right).
Treatment with a single injection of cisplatin induced robust reductions in 18FFMAU uptake in tumors (indicated in white) (A), compared to changes in uptake
seen in untreated mice (B). PET image color scale was calculated as follows: ½
background average  tumor max pixel.
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Figure 17. 18F-FMAU PET scans of mice bearing H460 tumors before and
after cisplatin treatment. Representative 18F-FMAU scans of mice bearing H292
(cisplatin-resistant) xenografts at baseline (left) and after 24 hours (right).
Treatment with a single injection of cisplatin induced negligible changes in 18FFMAU uptake in tumors (indicated in white) (A), compared to changes in uptake
seen in untreated mice (B). PET image color scale was calculated as follows: ½
background average  tumor max pixel.
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3.3. Systemic distribution and clearance of
cisplatin treatment

18F-FMAU

was not affected by

Representative mice from each treatment group was measured with 60minute dynamic scans after tracer injection to monitor

18F-FMAU

distribution and

clearance. Time activity curves describing activity over time were generated to
determine if any differences in clearance were observed in tumor, liver, and muscle
between treated and untreated mice (Figure 18A and B).
To ensure that cisplatin did not alter systemic

18F-FMAU

distribution in a

way which would affect tumor uptake, radioactivity was measured in bulk resected
tissues. Following the second PET scan, mice were euthanized and resected
tissues of interest were measured with gamma scintigraphy, with activity measured
as %i.d./cc. Treated mice maintained slightly higher levels of activity in whole
blood compared to untreated mice. In animals bearing H460 tumors, this was
measured as mean normalized %i.d./gram of 2.04% ± 0.84% in blood samples of
treated mice compared to 1.19% ± 0.54% in control mice. In mice bearing H292
tumors, normalized %i.d./gram of blood samples was measured as 1.31% ± 0.40%
in treated mice compared to 0.84% ± 0.43% in untreated mice. However, these
differences were not significant for mice bearing H292 or H460 tumors (p=0.52 and
0.53, respectively) (Figure 18C and D). In all groups, non-tumor tissues exhibited
no significant difference between mice treated with cisplatin compared to untreated
mice.

This suggests that systemic tissue retention of

18F-FMAU

was not

significantly altered by cisplatin treatment in a way which could confound tumor
analysis.

Resected H292 tumors showed no difference in activity between

cisplatin-treated and untreated tumors. Similarly to the results seen by PET,

18F-
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FMAU retention in H460 tumors treated with cisplatin was significantly lower than
untreated H460 tumors (*p=0.017).
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Figure 18. Cisplatin treatment did not alter clearance or biodistribution of
18F-FMAU in mice.
Representative curves of tracer uptake over time, as
measured by 60-minute dynamic scan, in cisplatin-treated mice bearing H460
tumors demonstrate that 18F-FMAU clearance is not altered in liver or muscle
tissues (A) compared to tissues in untreated mice (B). Uptake was reduced in
H460 tumors, consistent with whole body PET data of 18F-FMAU uptake following
cisplatin. Measured activity in bulk resected tissues from treated mice bearing
H460 or H292 tumors was normalized to untreated controls. Relative activity
suggests that cisplatin treatment does not significantly alter systemic
biodistribution of 18F-FMAU. As seen in PET, H460 tumors showed a significant
reduction in 18F-FMAU retention after cisplatin treatment compared to controls
(*p=0.17). While 18F-FMAU in the blood pool increased after cisplatin treatment,
these effects were not determined to be statistically significant in mice bearing
either H460 or H292 tumors (p=0.52 and 0.53, respectively)
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3.4.

18F-FMAU

metabolism was not altered by cisplatin treatment

Following euthanasia, serum of whole blood samples from representative
animals in each treatment group was analyzed with HPLC.
measured with gamma scintigraphy to detect

18F-FMAU

Fractions were

and any relevant

metabolites, as represented by peaks in corresponding fractions. Samples were
compared to HPLC curves of pure
injections (Figure 19A).

18F-FMAU

samples retained prior to animal

The majority of activity detected in the serum

corresponded to unmetabolized

18F-FMAU,

with small amounts of metabolite

noted as separate peak(s). Comparison of serum from mice treated with cisplatin
(Figure 19C) to serum from untreated mice (Figure 19B) suggests that a single
injection of cisplatin does not cause any measurable change in
metabolism. Thus, changes in

18F

18F-FMAU

activity in tumors is unlikely to be caused by

uptake of functionally different metabolites which retain 18F conjugation.
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Figure 19. 18F-FMAU metabolites represent a negligible fraction of 18F-FMAU
detected in the blood and are not significantly altered by cisplatin treatment.
HPLC analysis of serum from cisplatin-treated and control mice was performed
after sacrifice following the second PET scan. Peaks of activity in resulting
fractions were detected with gamma-scintigraphy, and were compared to curves
generated from HPLC of a sample of synthesized 18F-FMAU (A). Although trace
amounts of metabolites are seen in serum, the majority of activity corresponds with
18F-FMAU in treated (B) and untreated mice (C).
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4. Discussion
As a functional analogue of thymidine like 18F-FLT, 18F-FMAU was originally
tested as a marker for proliferation in tumor imaging (181, 182, 195). However,
FMAU phosphorylation has been shown to be primarily phosphorylated by TK2.
Unlike TK1, TK2 activity is not cell-cycle dependent, and is closely associated with
mitochondrial DNA synthesis. While this understanding confounds the association
between

18F-FMAU

retention and cellular proliferation, it provides new

opportunities for the use of

18F-FMAU

PET.

In this work, we present evidence that

18F-FMAU

PET may be useful in

identifying early response to chemotherapy in non-small cell lung tumors. Previous
work in our lab had demonstrated that mild cellular stress, such as nutritional
deprivation, could induce a transient increase in FMAU uptake and retention in
multiple cancer cell lines (102). These cells demonstrated increased TK2 activity
and FMAU retention, while TK1 activity and FLT retention dropped.

This

suggested that, while proliferation (and associated FLT phosphorylation) slowed
during cellular stress, a “flare” effect may be observed in FMAU retention which
could indicate a stress response. Unlike nutritional or oxidative pressures, cisplatin
treatment induces a very strong genotoxic effect. Interestingly, in vitro uptake
assays of

18F-FMAU

showed a flare in uptake following cisplatin treatment in

cisplatin-resistant H292 cells (Fig. 2B). This effect was not seen in cisplatinsensitive H460 cells. Although unexpected, increased FMAU retention in H292
cells could be indicative of a cellular stress response—one which is perhaps more
robust in overcoming the effects of cisplatin.
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This “flare” effect was not seen in mouse studies of

18F-FMAU

PET which

utilized the same tumor cell lines (Fig.3). However, an extremely significant drop
in

18F-FMAU

retention was measured in H460 tumors treated with cisplatin

compared to controls, while no difference was seen with cisplatin treatment in
H292 tumors. The reduced uptake in the H460 tumors, which were more likely to
respond to cisplatin treatment the H292 tumors, occurred within 24 hours of a
single injection of cisplatin. This was well before any measurable changes in tumor
size were evident, indicating that 18F-FMAU PET was sensitive enough to measure
very early changes in H460 metabolism induced by cisplatin.
It is important to note that, while a flare was seen in H292 cells in vitro, this
effect was measured with a relatively high dose of cisplatin (IC50 value as
determined by MTT).

In vivo, the therapeutic dose is limited by systemic

bioavailability and toxicity. Thus, the cisplatin dose to which the H292 tumors were
exposed in mice may not have been powerful enough to alter tumor cell
metabolism and 18F-FMAU retention. Realistically, chemotherapeutic doses in the
clinic often fall short of the amount of drug required to kill tumors.
To better understand these data, we will perform protein analyses of both
cell lines to measure TK2 presence in the presence or absence of cisplatin. This
should ensure that TK2 protein levels are not affected by cisplatin in a way which
could confound the imaging data. Further, we may pursue measurements of
mitochondrial mass in each cell line before and after cisplatin treatment, to
ascertain the role of mitochondrial proliferation in FMAU uptake in these cells. This
could provide insight into the differences seen in FMAU uptake following cisplatin
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treatment of these cells, as well as the inconsistencies observed between cell
studies and animal PET studies.
While we did not measure a flare with
response to cisplatin,

18F-FMAU

18F-FMAU

uptake in either tumor in

PET was able to differentiate between cisplatin-

sensitive and cisplatin-resistant tumors. Moreover, the sensitive tumors were
distinguishable 24 hours into treatment, after a single dose. We believe that this
is compelling evidence for the use of

18F-FMAU

PET in predicting non-small cell

lung cancer response early into cisplatin treatment. To better understand the
potential of this tracer for oncological imaging, further study of
tumors is necessary.

18F-FMAU

PET in
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CHAPTER 4. SUMMARY
Cancer patients face a myriad of challenges in combating tumors, which are
often as unique as the person harboring them. Oncological PET offers a variety
of opportunities for researchers and clinicians to use non-invasive imaging in the
personalization of cancer treatment. Although many forms of imaging can provide
information on tumor location, size, and general morphology, PET can measure
metabolic and biochemical parameters of tumors. Due to the impressive sensitivity
of PET, thoughtfully designed tracers can be used to quantify specific processes
in tissues. In the case of PET for tumors, information about metabolic activity or
cellular behavior can define or drastically alter therapeutic strategies selected to
treat a cancer.
Information about tumor biochemistry is assessed non-invasively with PET
imaging. Unlike more traditional means of tumor profiling, such as tissue biopsy,
PET does not require invasive procedures and provides information about the
entire tumor or multiple tumor within an individual.

This makes longitudinal

monitoring of tumor behavior much easier on the patient, and can be used to
measure changes in tumor activity over time or as a result of therapy. Subtle
changes in tumor behavior can be detected with PET well before changes in
overall morphology are measurable, making PET an ideal means of detecting early
response to treatment. The heterogeneic nature of tumors leads to a wide variety
of responses to conventional or experimental therapies.

Early detection of

response in patient populations could identify patients who are likely to respond to
a therapy and, more importantly, those who are unlikely to respond. Patients with
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tumors predicted to be resistant can move on to other strategies before there is
obvious growth or spread of the tumor and thus avoid further ineffective treatment
regimen.
PET has become an important method for measuring and monitoring
nanoparticle delivery to solid tumors, particularly in preclinical studies. Successful
delivery of nanoparticles to solid tumor tissue is necessary for the successful
implementation of nanoparticle-based cancer treatments.

Unfortunately,

nanoparticle delivery is highly variable in patient tumors, which has led to an effort
in identifying therapeutic strategies for manipulating nanoparticle delivery as
needed. We have shown that PET with radiolabeled nanoparticles is an elegant
means to not only measure nanoparticle delivery to tumors, but to monitor changes
induced by combination therapy. We found that bevacizumab-induced changes in
vascularity of colon tumor xenografts was able to significantly alter nanoparticle
delivery after only one week of treatment. Further, these effects were detectable
by PET with a

64Cu-labeled

liposome. By utilizing tracer nanoparticles that mimic

drug-loaded nanoparticles, researchers can utilize PET to define and monitor
therapeutic strategies to augment nanoparticle delivery to solid tumors.
The biochemistry of the tracers used for PET define the type of information
that is acquired with a PET scan. In the clinic, the most commonly used tracers
are small molecules which specifically integrate into biological processes of
interest. Similarly,

18F-FMAU

is a thymidine analogue studied for tumor imaging

with PET. In our studies of both cells and mouse models of lung cancer, we found
that changes

18F-FMAU

uptake may be indicative of tumor response to treatment
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with cisplatin.

18F-FMAU

uptake in cisplatin-responsive tumors dropped

dramatically during treatment, while resistant tumors showed little change in tracer
uptake.

Importantly, these changes were seen within 24 hours of treatment

initiation, and only one injection of cisplatin.

18F-FMAU

PET was able to clearly

differentiate between resistant and sensitive tumors very early into treatment. This
supports the promise of PET for imaging early response to treatment in lung
tumors undergoing chemotherapy.
In conclusion, the advantages of oncological PET imaging extend far
beyond the limits of defining tumor morphology. PET can be utilized to detect
treatment-induced changes in tumor behavior with tracers that range from smallsmall molecule to nanoparticles. In the era of targeted therapies and precision
medicine, PET is a powerful tool to measure, monitor, and predict tumor response
to treatment. In this way, PET can help physicians select better therapeutic
strategies that are tailored to the specific needs of each individual patient.
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An important pillar of precision medicine for oncology is the ability to identify
patients who respond to treatment early into their therapy. Positron emission
tomography (PET) allows physicians and researchers to measure changes in
tumor behavior prior to noticeable differences in morphology.
Objective: Determine the utility of multiple tracers for PET in assessing
early changes in tumor activity that result from treatment.
Methods: Two tracers for PET were studied.

64Cu-labeled

liposomes were

used to assess changes in liposome delivery two solid colon tumors early into
treatment with bevacizumab (Bev).

18F-FMAU

thymidine analog (1-(2'-deoxy-2'-

fluoro-beta-D-arabinofuranosyl)thymine), was utilized to detect early response to
cisplatin treatment in non-small cell lung tumor models. Scans were analyzed
before and after short-term therapy to determine changes in tracer retention which
suggest therapeutic response.
Results: In each study PET was able to detect changes in tumor behavior
which occurred early into treatment. After two injections of Bev over one week,
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liposome delivery was significantly reduced as measured by PET. In lung tumors,
24 hours of cisplatin treatment induced significant drops in

18F-FMAU

retention in

cisplatin sensitive tumors compared to resistant tumors.
Conclusion: PET imaging with a variety of tracers can provide information
about tumor response to a broad spectrum of treatments. Thus, PET is a powerful
tool for personalized therapy of cancer.
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